Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Patients with anxious depression are typically more difficult to treat with monoaminergic antidepressants compared to those with nonanxious depression. Although novel research has shown that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapidly acting, relatively sustained effects in treating depression, we predicted that, consistent with the existent literature on traditional antidepressants, patients with anxious depression would have a poorer antidepressant response. METHOD: Twenty-six inpatients with treatment-resistant major depressive disorder (MDD) (DSM-IV criteria) received a single infusion of ketamine (0.5 mg/kg over 40 minutes) from January 2006-March 2013 and were followed for 28 days. A post hoc analysis compared treatment response and relapse using the Montgomery-Asberg Depression Rating Scale (MADRS) in patients with anxious versus nonanxious depression. Anxious depression was defined as MDD plus a Hamilton Depression Rating Scale anxiety/somatization factor score ≥ 7. RESULTS: Both anxious and nonanxious depressed patients responded positively to ketamine. A linear mixed model controlling for baseline with the MADRS revealed a significant group main effect (P = .03) and group-by-time interaction (P = .01). Post hoc tests indicated that patients with anxious depression had significantly fewer depression symptoms compared to those with nonanxious depression at days 1 through 5, 9 through 12, 15 through 17, and 25, with no significant group differences in dissociative (P = .62) or psychotic (P = .41) side effects. Regarding responders, patients with anxious depression relapsed significantly later than those with nonanxious depression (median ± SE = 19.0 ± 17.9 vs 1.0 ± 0.0 days to relapse, respectively; χ² = 9.30; P = .002). CONCLUSIONS: Unexpectedly, patients with anxious depression responded better to ketamine than those with nonanxious depression, with longer time to relapse and no side effect differences. This finding gives promise for the role of novel glutamatergic medications for the treatment of those with anxious depression, a traditionally difficult-to-treat subgroup of depressed patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00088699.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to these dissociative properties, multiple controlled clinical studies indicate that ketamine effectively reduces symptoms of depression and is particularly effective in anxious depression (Ionescu et al, 2014).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Ionescu et al, 2014
In the citing paper
“Another study also found efficacy for quetiapine therapy in patients with anxious depression, but did not directly compare this with a nonanxious depressed patient group and the sample size was very small (n ¼ 9) [54].”
From Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome (2018) · cites this paper as [54]
Citations
Cites
Still being checked.
Cited by
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“60,61 More recently, an intranasal form of esketamine (a ketamine enantiomer) has been developed, which has shown good effect with continued treatment in combination with an oral antidepressant 26 and has now been approved by the FDA for restricted use in TRD.”
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citationComorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment
Choi, K. W., Kim, Y.-K., & Jeon, H. J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_14 · Cited by 304
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Self-citationIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
“2014b] [Clinical Trials identifier: NCT02122562] or dimensional anxious depression [Ionescu et al. 2014], to develop treatment response biomarkers and other surrogate endpoints for personalized antidepressant treatment selection.”
BackgroundSelf-citationKiraly, D. D., Horn, S. R., Van Dam, N. T., Costi, S., Schwartz, J., Kim-Schulze, S., Patel, M., Hodes, G. E., Russo, S. J., Merad, M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.31 · Cited by 186
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179
Self-citationTreatment-refractory anxiety; definition, risk factors, and treatment challenges
Roy-Byrne, P. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/proybyrne · Cited by 147
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“Preliminary evidence suggests that anxious depression may respond better to ketamine treatment than non-anxious depression [49, 50].”
BackgroundSelf-citationGlue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117705089 · Cited by 144
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.194 · Cited by 142
Gaspersz, R., Nawijn, L., Lamers, F., & Penninx, B. W. J. H. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000376 · Cited by 139
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
Self-citationTowards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Self-citationKetamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Ren, Z., Pribiag, H., Jefferson, S. J., Shorey, M., Fuchs, T., Stellwagen, D., & Luscher, B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.009 · Cited by 114
“Ketamine is especially effective in otherwise treatmentresistant forms of MDD associated with high anxiety (27).”
BackgroundCusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N., Eikermann, M., Durham, K., Swee, M. B., Chang, T., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 111
Self-citationA single infusion of ketamine improves depression scores in patients with anxious bipolar depression
Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2015) · Bipolar Disorders · doi:10.1111/bdi.12277 · Cited by 104
Self-citationGill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
The Role of Chronic Stress in Anxious Depression
Ross, R. A., Foster, S. L., & Ionescu, D. F. (2017) · Chronic Stress · doi:10.1177/2470547016689472 · Cited by 92
“Ketamine (a glutamatergic modulator that has rapid (within hours) and robust (across many symptoms) antidepressant effects) can be utilized to specifically probe differences in the brains of depressed patients with and without anxiety pre- and post-ketamine treatment, because patients with anxious depression respond b…”
BackgroundSelf-citationRisks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
Self-citationPennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.026 · Cited by 77
Self-citationKetamine for Bipolar Depression: A Systematic Review
Bahji, A., Zarate, C. A., & Vazquez, G. H. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 65
Self-citationPsychometric Properties of the DASS-21 Among Latina/o College Students by the US-Mexico Border
Camacho, Á., Cordero, E. D., & Perkins, T. (2016) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-016-0415-1 · Cited by 74
Thomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Ketamine for depression: evidence, challenges and promise
Zarate, C. A., & Niciu, M. J. (2015) · World Psychiatry · doi:10.1002/wps.20269 · Cited by 61
Self-citationBanov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 66
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 65
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 100
Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoeppner, B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2019) · Depression and Anxiety · doi:10.1002/da.22875 · Cited by 50
Self-citationVidal, S., Gex-Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A., Sterpenich, V., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 52
Daly, E. J., Turkoz, I., Salvadore, G., Fedgchin, M., Ionescu, D. F., Starr, H. L., Borentain, S., Trivedi, M. H., Thase, M. E., & Singh, J. B. (2021) · Depression and Anxiety · doi:10.1002/da.23193 · Cited by 46
Self-citationZhang, H., Xue, W., Wu, R., Gong, T., Tao, W., Zhou, X., Jiang, J., Zhang, Y., Zhang, N., Cui, Y., et al. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/761238 · Cited by 64
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y.-K. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 42
Liu, W., Zhou, Y., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Li, H., Chen, L., & Ning, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.012 · Cited by 45
Camacho, Á., González, P., Buelna, C., Emory, K., Talavera, G. A., Castañeda, S. F., Espinoza, R. A., Howard, A. G., Perreira, K. M., Isasi, C. R., et al. (2015) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1120-4 · Cited by 49
Can psychological features predict antidepressant response to rTMS? A Discovery–Replication approach
Krepel, N., Rush, A. J., Iseger, T. A., Sack, A. T., & Arns, M. (2019) · Psychological Medicine · doi:10.1017/s0033291718004191 · Cited by 49
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
Self-citationEffects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia
Kandratavicius, L., Balista, P. A., Wolf, D. C., Abrão, J., Évora, P. R. B., Rodrigues, A. J., Chaves, C., Maia‐de‐Oliveira, J. P., Leite, J. P., Dursun, S. M., et al. (2015) · BMC Neuroscience · doi:10.1186/s12868-015-0149-3 · Cited by 46
The positive effect on ketamine as a priming adjuvant in antidepressant treatment
Melo, A., Kokras, N., Dalla, C., Ferreira, C., Ventura-Silva, A. P., Sousa, N., & Pêgo, J. M. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.66 · Cited by 41
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Georgiou, P., Farmer, C., Medeiros, G. C., Yuan, P., Johnston, J. N., Kadriu, B., Gould, T. D., & Zarate, C. A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.036 · Cited by 38
Self-citationLow-dose ketamine for treatment resistant depression in an academic clinical practice setting
Feifel, D., Malcolm, B., Boggie, D., & Lee, K. C. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.043 · Cited by 34
Association between depression subtypes and response to repeated‐dose intravenous ketamine
Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., Chen, L., Zhang, B., Walter, M., Li, M., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13096 · Cited by 35
Panic Disorder: A Review of Treatment Options
Ziffra, M. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0014 · Cited by 33
Vila-Merkle, H., González-Martínez, A., Campos-Jiménez, R., Martínez‐Ricós, J., Teruel‐Martí, V., Lloret, A., Blasco‐Serra, A., & Cervera‐Ferri, A. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1122163 · Cited by 32
Chen, M., Wu, H.-J., Li, C., Lin, W.-C., Bai, Y., Tsai, S., Hong, C., Tu, P., Cheng, C., & Su, T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.045 · Cited by 26
Zhou, Y., Liu, W., Zheng, W., Wang, C., Zhan, Y., Lan, X., Zhang, B., Zhang, C., & Ning, Y. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.001 · Cited by 23
Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients
Vidal, S. I., Jermann, F., Aubry, J., Richard-Lepouriel, H., & Kosel, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001305 · Cited by 24
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Mallick, F., & McCullumsmith, C. B. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0680-7 · Cited by 22
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Chen, M., Lin, W.-C., Wu, H.-J., Bai, Y., Li, C., Tsai, S., Hong, C., Tu, P., Cheng, C., & Su, T. (2020) · CNS Spectrums · doi:10.1017/s1092852920001194 · Cited by 24
Constantino, J. L., Godschalk, M., van Dalfsen, J. H., Veraart, J. K. E., Spijker, J., van Exel, E. R., Schoevers, R. A., & Kamphuis, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116355 · Cited by 23
Development of New Psychopharmacological Agents for Depression and Anxiety
Schatzberg, A. F. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.009 · Cited by 19
Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats
Pekary, A. E., Sattin, A., & Lloyd, R. L. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.003 · Cited by 21
A review of ketamine’s role in ECT and non-ECT settings
Jankauskas, V., Necyk, C., Chue, J., & Chue, P. S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157233 · Cited by 20
Pang, L., Cui, M., Dai, W., Kong, J., Chen, H., & Wu, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.586104 · Cited by 19
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham, A., Avila-Quintero, V. J., Bloch, M. H., & Dwyer, J. B. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0047 · Cited by 20
Beaudequin, D. A., Can, A., Dutton, M., Jones, M., Gallay, C. C., Schwenn, P., Yang, C., Forsyth, G., Simcock, G. P., Hermens, D. F., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02925-1 · Cited by 20
Vila-Merkle, H., González-Martínez, A., Campos-Jiménez, R., Martínez‐Ricós, J., Teruel‐Martí, V., Blasco‐Serra, A., Lloret, A., Celada, P., & Cervera‐Ferri, A. (2021) · Biomedicines · doi:10.3390/biomedicines9070783 · Cited by 18
Martín-González, E., Prados-Pardo, Á., Mora, S., Flores, P., & Moreno, M. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4819-y · Cited by 17
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Yuan, S., Luo, X., Chen, X., Wang, M., Hu, Y., Zhou, Y., Ning, Y., & Zhang, B. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.125 · Cited by 15
Lan, X., Wang, C., Zhang, F., Liu, H., Fu, L., Li, W., Ye, Y., Hu, Z., Mai, S., Ning, Y., et al. (2023) · General Psychiatry · doi:10.1136/gpsych-2023-101007 · Cited by 19
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 20
NMDA Antagonists for Treatment-Resistant Depression
Farber, N. B. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_165 · Cited by 15
Roméo, B., Choucha, W., Fossati, P., & Rotgé, J. (2016) · L Encéphale · doi:10.1016/j.encep.2016.06.005 · Cited by 13
Li, X.-T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03069-6 · Cited by 15
Current Trends in Identifying Rapidly Acting Treatments for Depression
Ionescu, D. F., & Papakostas, G. I. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0075-4 · Cited by 13
Self-citationZheng, W., Yang, X.-H., Gu, L.-M., Tan, J.-Q., Zhou, Y.-L., Wang, C.-Y., & Ning, Y.-P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.081 · Cited by 11
Cuomo, A., Pardossi, S., Barillà, G., Carmellini, P., Firenzuoli, B., Tarantino, F., Tinturini, R., & Fagiolini, A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.01.059 · Cited by 7
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Schmidt, M. E., Moyer, J. A., Kezic, I., Zhou, X., Samtani, M. N., Bleys, C., Dallas, S., Salvadore, G., & Drevets, W. C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.03.007 · Cited by 8
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Landrigan, J., Shawaf, F., Dwyer, Z., Abizaid, A. B., & Hayley, S. P. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.08.015 · Cited by 8
Stamenković, D., Selvaraj, S., Venkatraman, S., Arshad, A., Rančić, N., Dragojevic-Simic, V. M., Miljković, M. N., & Cattano, D. (2020) · Minerva Anestesiologica · doi:10.23736/s0375-9393.20.14259-7 · Cited by 10
David, J., Mousset, M., Trombetti, K. A., Sayasouk, B., Neilsen, C., Suorsa, P., Ruben, M., Rubén, E., Thiessen, J., Pychewicz, T., et al. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114377 · Cited by 6
Ketamine and Depression: A Review
Ryan, W. C., Marta, C. J., & Koek, R. J. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.40 · Cited by 6
Gunduz‐Bruce, H., Kenney, J. G., Changlani, S., Peixoto, A. J., Gueorguieva, R. V., Leone, C. A., & Stachenfeld, N. S. (2017) · Experimental Physiology · doi:10.1113/ep086212 · Cited by 6
Sartori, D. P., de Oliveira, N. F., Valentim, J. T., Silva, D. M. A., Mallmann, A. S. V., Oliveira, I. C. M., Chaves, R., Capibaribe, V. C. C., de Carvalho, A. M. R., Rebouças, M. D. O., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112487 · Cited by 10
Foster, S. L., Petrie, S. R., Mischoulon, D., & Fava, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_8 · Cited by 6
Ketamine’s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies
Averill, L. A., Murrough, J. W., & Abdallah, C. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_7 · Cited by 6
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson, S. T., Ostroff, R. B., Katz, R. B., & Krystal, J. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_16 · Cited by 5
RETRACTED–Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study
Mills, N. T., Nikolin, S., Glozier, N., Barton, D., Baune, B. T., Fitzgerald, P. B., Glue, P., Sarma, S., Rodgers, A., Hadzi-Pavlovic, D., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.250 · Cited by 5
RetractedLiang, Y., You, Z., Chen, X., Liu, G., Li, W., Wang, C., Lan, X., Luo, Z., Mai, S., Zhang, F., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.084 · Cited by 3
Dalhuisen, I., Biemans, T., Vos, C. F., ter Hark, S. E., van Oostrom, I., Spijker, J., Wijnen, B. F. M., van Exel, E. R., van Mierlo, H. C., de Waardt, D., et al. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02012-0 · Cited by 3
Twohig, P. A., & Huckfeldt, V. (2016) · International Journal of Medical Students · doi:10.5195/ijms.2016.153 · Cited by 3
Control of glutamate homeostasis in the Gram-positive model organism Bacillus subtilis
Stannek, L. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5321 · Cited by 3
Neuropeptidergic systems in psychiatric disorders
Hodzic, S., & Riedemann, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1654292 · Cited by 2
Wilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Syed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 2
Schoretsanitis, G., & Hasler, G. (2015) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2015.02420 · Cited by 1
Identification and management of anxious depression in patients with treatment-resistant depression
Hershenberg, R., Rapaport, M. H., & Weischedel, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00029-3 · Cited by 3
El valor del medicamento desde una perspectiva social
Hidalgo‐Vega, Á. (2018) · doi:10.37666/i4-2018 · Cited by 3
Metadata
- Authors
- Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., Slonena, E. E., Vande Voort, J. L., Brutsche, N. E., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-09-25
- Volume
- 75
- Issue
- 09
- Pages
- e932-e938
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2033541113
- Cited by
- 111
- References
- 0
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 15 · 2019: 5 · 2018: 9 · 2017: 12 · 2016: 11 · 2015: 15 · 2014: 3
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- anxious depression, ketamine, antidepressant response, relapse, NMDA receptor antagonists, rapid-acting antidepressants
- MeSH terms
- Antidepressive Agents, Anxiety Disorders, Major Depressive Disorder, Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.